Phreesia Class Action Lawsuit Notice
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Source: Globenewswire
- Class Action Deadline: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, that they must apply to be lead plaintiff by July 13, 2026, or risk losing their right to compensation.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, leading to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, highlighting its extensive experience and success in handling such cases.
- Investor Action Advice: Investors can visit Rosen Law Firm's website or call toll-free at 866-767-3653 for more information, and are advised to select qualified counsel with a proven track record to ensure their rights are effectively represented in the class action.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PHR
Wall Street analysts forecast PHR stock price to rise
12 Analyst Rating
12 Buy
0 Hold
0 Sell
Strong Buy
Current: 9.050
Low
24.00
Averages
29.09
High
35.00
Current: 9.050
Low
24.00
Averages
29.09
High
35.00
About PHR
Phreesia, Inc. is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations. The Company's solutions include software-as-a-service (SaaS)-based integrated tools that manage patient access, registration, and payments. In addition, its solutions include clinical assessments to screen patients for a variety of physical, behavioral and mental health conditions, helping providers to understand their patients and connect them to needed services, resulting in improved health outcomes. Its Technology solutions segment provides life sciences companies, health plans and other payer organizations (payers), patient advocacy, public interest and other not-for-profit organizations with a channel for direct communication with patients. The Company's solutions also include additional products and services, such as the MediFind provider directory, which helps patients find care based on providers' specific clinical expertise.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Phreesia Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Phreesia for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 8, 2025, and March 30, 2026, with a deadline to contact the firm by July 13, 2026.
- False Statements Allegation: The complaint alleges that Phreesia made false and misleading statements regarding its long-term growth outlook, claiming confidence in growth projections for fiscal year 2027 despite uncertainties that could jeopardize revenue targets, leading to investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to act before the class is certified to ensure their rights are protected and avoid being absent class members.
- Market Reaction Impact: As the market learned the truth about Phreesia, investor losses intensified, indicating a lack of confidence in the company's growth commitments, which could negatively impact its future stock price.
See More
Multiple Companies Face Class Action Lawsuits
- Phreesia Lawsuit: Phreesia Inc. is accused of making false statements from May 8, 2025, to March 30, 2026, undermining investor confidence in its 2027 revenue targets, with a lead plaintiff deadline of July 13, 2026.
- Sportradar Violations: Sportradar Group AG faces allegations of collaborating with black-market gambling operators and failing to disclose compliance process weaknesses, with investors needing to file a lead plaintiff motion by July 17, 2026, potentially leading to significant financial repercussions.
- Commvault Sales Issues: Commvault Systems Inc. is accused of not disclosing the impact of sales types on annual recurring revenue (ARR) growth, with a lead plaintiff deadline of July 17, 2026, which could distort financial forecasts and investor expectations.
- Veritone Financial Misstatements: Veritone, Inc. is charged with inaccurately recording revenue and costs, necessitating a restatement of financial statements, with a lead plaintiff deadline of July 20, 2026, which may harm the company's reputation and shareholder confidence.
See More
Phreesia Shareholders File Class Action Amid Marketing Commitment Concerns
- Class Action Filed: A class action lawsuit has been initiated against Phreesia, Inc. (NYSE:PHR) by shareholders who purchased securities between May 8, 2025, and March 30, 2026, due to the company's failure to disclose deteriorating pharmaceutical marketing commitments, highlighting a significant gap between internal knowledge and public disclosures.
- Stock Price Plunge: Following the revelation on March 30, 2026, that pharmaceutical manufacturers were committing far less than anticipated, Phreesia's stock price fell by $3.03, representing a 27% decline, which directly impacted investor confidence and the company's market capitalization.
- Discrepancy in Information: The lawsuit alleges that Phreesia's management had ongoing access to critical pharmaceutical marketing commitment data throughout the class period but publicly maintained that spending patterns remained consistent with previous years, leading investors to purchase shares at artificially inflated prices.
- Legal Implications and Investor Protection: The filing of this lawsuit raises important questions about the timing of internal risk awareness versus public disclosures, with investors needing to submit claims by July 13, 2026, to protect their rights, underscoring the need for improved corporate governance and transparency.
See More
Phreesia Class Action Lawsuit Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
See More
Phreesia Class Action Lawsuit Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE:PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants incur no upfront costs as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden, thereby lowering the barrier to participation.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, which led to investor losses when the truth emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
See More
Phreesia Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, with a deadline of July 13, 2026, to apply as lead plaintiffs.
- Allegations: The complaint alleges that Phreesia and its executives violated federal securities laws by failing to disclose the true state of slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment.
- Revenue Guidance Cut: On March 30, 2026, Phreesia revised its fiscal 2027 revenue guidance down to $510-$520 million, a reduction of $35 million to $49 million from the previous range, causing the stock to plummet by 21% to 28%.
- Investor Rights Protection: Affected investors are encouraged to contact the law firm via phone or email to discuss their legal rights and potential claims, with no cost or obligation for the consultation.
See More
Phreesia Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Phreesia for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between May 8, 2025, and March 30, 2026, with a deadline to contact the firm by July 13, 2026.
- False Statements Allegation: The complaint alleges that Phreesia made false and misleading statements regarding its long-term growth outlook, claiming confidence in growth projections for fiscal year 2027 despite uncertainties that could jeopardize revenue targets, leading to investor losses.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected investors to act before the class is certified to ensure their rights are protected and avoid being absent class members.
- Market Reaction Impact: As the market learned the truth about Phreesia, investor losses intensified, indicating a lack of confidence in the company's growth commitments, which could negatively impact its future stock price.
See More
Multiple Companies Face Class Action Lawsuits
- Phreesia Lawsuit: Phreesia Inc. is accused of making false statements from May 8, 2025, to March 30, 2026, undermining investor confidence in its 2027 revenue targets, with a lead plaintiff deadline of July 13, 2026.
- Sportradar Violations: Sportradar Group AG faces allegations of collaborating with black-market gambling operators and failing to disclose compliance process weaknesses, with investors needing to file a lead plaintiff motion by July 17, 2026, potentially leading to significant financial repercussions.
- Commvault Sales Issues: Commvault Systems Inc. is accused of not disclosing the impact of sales types on annual recurring revenue (ARR) growth, with a lead plaintiff deadline of July 17, 2026, which could distort financial forecasts and investor expectations.
- Veritone Financial Misstatements: Veritone, Inc. is charged with inaccurately recording revenue and costs, necessitating a restatement of financial statements, with a lead plaintiff deadline of July 20, 2026, which may harm the company's reputation and shareholder confidence.
See More
Phreesia Shareholders File Class Action Amid Marketing Commitment Concerns
- Class Action Filed: A class action lawsuit has been initiated against Phreesia, Inc. (NYSE:PHR) by shareholders who purchased securities between May 8, 2025, and March 30, 2026, due to the company's failure to disclose deteriorating pharmaceutical marketing commitments, highlighting a significant gap between internal knowledge and public disclosures.
- Stock Price Plunge: Following the revelation on March 30, 2026, that pharmaceutical manufacturers were committing far less than anticipated, Phreesia's stock price fell by $3.03, representing a 27% decline, which directly impacted investor confidence and the company's market capitalization.
- Discrepancy in Information: The lawsuit alleges that Phreesia's management had ongoing access to critical pharmaceutical marketing commitment data throughout the class period but publicly maintained that spending patterns remained consistent with previous years, leading investors to purchase shares at artificially inflated prices.
- Legal Implications and Investor Protection: The filing of this lawsuit raises important questions about the timing of internal risk awareness versus public disclosures, with investors needing to submit claims by July 13, 2026, to protect their rights, underscoring the need for improved corporate governance and transparency.
See More
Phreesia Class Action Lawsuit Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE: PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and success in this field.
See More
Phreesia Class Action Lawsuit Reminder
- Class Action Notice: Rosen Law Firm reminds investors who purchased Phreesia (NYSE:PHR) common stock between May 8, 2025, and March 30, 2026, to apply as lead plaintiffs by July 13, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Participants incur no upfront costs as the law firm operates on a contingency fee basis, allowing investors to pursue claims without financial burden, thereby lowering the barrier to participation.
- Lawsuit Background: The lawsuit alleges that Phreesia made false or misleading statements during the class period, concealing adverse facts such as weakened pharmaceutical marketing commitments in its Network Solutions segment, which led to investor losses when the truth emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, ranked first by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
See More
Phreesia Faces Class Action Lawsuit; Investors Encouraged to Contact Attorneys
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against Phreesia in the U.S. District Court for Delaware on behalf of investors who purchased shares between May 8, 2025, and March 30, 2026, with a deadline of July 13, 2026, to apply as lead plaintiffs.
- Allegations: The complaint alleges that Phreesia and its executives violated federal securities laws by failing to disclose the true state of slowing demand and reduced visibility in key revenue streams, particularly weakened pharmaceutical marketing commitments in its Network Solutions segment.
- Revenue Guidance Cut: On March 30, 2026, Phreesia revised its fiscal 2027 revenue guidance down to $510-$520 million, a reduction of $35 million to $49 million from the previous range, causing the stock to plummet by 21% to 28%.
- Investor Rights Protection: Affected investors are encouraged to contact the law firm via phone or email to discuss their legal rights and potential claims, with no cost or obligation for the consultation.
See More
